Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tumors in the real world.

Nishida T, Sakai Y, Takagi M, Ozaka M, Kitagawa Y, Kurokawa Y, Masuzawa T, Naito Y, Kagimura T, Hirota S; members of the STAR ReGISTry Study Group.

Gastric Cancer. 2019 Apr 30. doi: 10.1007/s10120-019-00966-4. [Epub ahead of print]

PMID:
31041650
2.

Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.

Yoo C, Ryu MH, Jo J, Park I, Ryoo BY, Kang YK.

Cancer Res Treat. 2016 Apr;48(2):546-52. doi: 10.4143/crt.2015.015. Epub 2015 Jun 22.

3.

Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.

Søreide K, Sandvik OM, Søreide JA, Gudlaugsson E, Mangseth K, Haugland HK.

Clin Transl Oncol. 2012 Aug;14(8):619-29. doi: 10.1007/s12094-012-0851-x. Epub 2012 Jul 18.

PMID:
22855146
4.

"Pediatric-type" gastrointestinal stromal tumors in adults: distinctive histology predicts genotype and clinical behavior.

Rege TA, Wagner AJ, Corless CL, Heinrich MC, Hornick JL.

Am J Surg Pathol. 2011 Apr;35(4):495-504. doi: 10.1097/PAS.0b013e31820e5f7d.

PMID:
21358303
5.

DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases.

Miettinen M, Wang ZF, Lasota J.

Am J Surg Pathol. 2009 Sep;33(9):1401-8. doi: 10.1097/PAS.0b013e3181a90e1a.

PMID:
19606013
6.

Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.

Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Cameron S, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Nilsson B, Kallio R, Junnila J, Vehtari A, Reichardt P.

JAMA Oncol. 2017 May 1;3(5):602-609. doi: 10.1001/jamaoncol.2016.5751.

7.

KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).

Lasota J, Miettinen M.

Semin Diagn Pathol. 2006 May;23(2):91-102. Review.

PMID:
17193822
8.

Pathology of gastrointestinal stromal tumors.

Foo WC, Liegl-Atzwanger B, Lazar AJ.

Clin Med Insights Pathol. 2012;5:23-33. doi: 10.4137/CPath.S9689. Epub 2012 Jul 17.

9.

DOG1 and PKC-θ are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors.

Kang GH, Srivastava A, Kim YE, Park HJ, Park CK, Sohn TS, Kim S, Kang DY, Kim KM.

Mod Pathol. 2011 Jun;24(6):866-75. doi: 10.1038/modpathol.2011.11. Epub 2011 Feb 25.

10.
11.

The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status.

West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, Zhu S, Ball CA, Nielsen TO, Patel R, Goldblum JR, Brown PO, Heinrich MC, van de Rijn M.

Am J Pathol. 2004 Jul;165(1):107-13.

12.

Expression of DOG1, PDGFRA, and p16 in Gastrointestinal Stromal Tumors.

Jung SH, Suh KS, Kang DY, Kang DW, Kim YB, Kim ES.

Gut Liver. 2011 Jun;5(2):171-80. doi: 10.5009/gnl.2011.5.2.171. Epub 2011 Jun 24.

13.

Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection.

Rutkowski P, Wozniak A, Dębiec-Rychter M, Kąkol M, Dziewirski W, Zdzienicki M, Ptaszynski K, Jurkowska M, Limon J, Siedlecki JA.

Cancer. 2011 Nov 1;117(21):4916-24. doi: 10.1002/cncr.26079. Epub 2011 Mar 31.

14.

Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes.

Liegl B, Hornick JL, Corless CL, Fletcher CD.

Am J Surg Pathol. 2009 Mar;33(3):437-46. doi: 10.1097/PAS.0b013e318186b158.

PMID:
19011564
15.

GSTT1 copy number gain and ZNF overexpression are predictors of poor response to imatinib in gastrointestinal stromal tumors.

Lee EJ, Kang G, Kang SW, Jang KT, Lee J, Park JO, Park CK, Sohn TS, Kim S, Kim KM.

PLoS One. 2013 Oct 4;8(10):e77219. doi: 10.1371/journal.pone.0077219. eCollection 2013.

16.

The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.

Osuch C, Rutkowski P, Brzuszkiewicz K, Bylina E, Limon J, Siedlecki JA.

Pol Przegl Chir. 2014 Jul;86(7):325-32. doi: 10.2478/pjs-2014-0057.

PMID:
25222580
17.

Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.

Lasota J, Miettinen M.

Histopathology. 2008 Sep;53(3):245-66. doi: 10.1111/j.1365-2559.2008.02977.x. Epub 2008 Feb 28. Review.

PMID:
18312355
18.

[The role of the DOG1 antibody in the diagnosis of gastrointestinal stromal tumours - GIST].

Gutierrez MR, Dorronsoro ML, Marco AM, Pérez IR, Villegas IA, Virseda JM.

An Sist Sanit Navar. 2011 May-Aug;34(2):245-51. Spanish.

19.

ETV1 mRNA is specifically expressed in gastrointestinal stromal tumors.

Jang BG, Lee HE, Kim WH.

Virchows Arch. 2015 Oct;467(4):393-403. doi: 10.1007/s00428-015-1813-9. Epub 2015 Aug 5.

PMID:
26243012
20.

Gastrointestinal stromal tumors: A multidisciplinary challenge.

Sanchez-Hidalgo JM, Duran-Martinez M, Molero-Payan R, Rufian-Peña S, Arjona-Sanchez A, Casado-Adam A, Cosano-Alvarez A, Briceño-Delgado J.

World J Gastroenterol. 2018 May 14;24(18):1925-1941. doi: 10.3748/wjg.v24.i18.1925. Review.

Supplemental Content

Support Center